Press Releases
Oct 22, 2024
Arbor Biotechnologies to Highlight New Preclinical Data Supporting Advancement of Pipeline Programs and Knock-In Applicability of Type V Nucleases at Upcoming Medical and Scientific Meetings
Oral presentation at ASN on lead program, ABO-101 for primary hyperoxaluria type 1 (PH1), supporting in vivo proof of pharmacology. On-track for year-end IND/CTA filing. Oral presentation at ALS One and a poster presentation at ESGCT on lead ALS programRead More
May 9, 2024
Arbor Biotechnologies Presents Data Supporting Clinical Development of ABO-101 and Robust Potential of Platform to Enable Therapeutic Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Presented data which, along with ongoing IND-enabling studies, demonstrate efficacy and pharmacology of ABO-101 in non-human primates (NHPs), supporting continued development as a potential novel gene editing therapy for patients with primary hyperoxaluria type 1 (PH1) Other presentations include preclinicalRead More
May 8, 2024
Arbor Biotechnologies Announces Acquisition of Serendipity
Serendipity brings proprietary gene editing assets from the lab of gene editing pioneer Feng Zhang, bolstering Arbor’s diverse toolbox of novel, next-generation editors and expanding potential therapeutic applications in reverse transcriptase-based editing and insertion of large regions of DNA Read More
Apr 22, 2024
Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Oral and poster presentations showcase data demonstrating pipeline progress and continued advancement of Arbor’s pipeline programs toward the clinic Oral presentation with data validating aspects of Arbor’s approach to the discovery and development of unique gene editors, outlines the identificationRead More
Mar 12, 2024
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next Generation Allogeneic CAR T Platform in Autoimmune Disease
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing Technology First Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 – AllogeneRead More
Jan 3, 2024
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six product candidates in CNS Initial product candidate will be developed for a target in amyotrophic lateralRead More
Dec 12, 2023
Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors
Arbor, a biotechnology company discovering and developing the next generation of genetic medicines, will leverage Ginkgo’s R&D services to further optimize Arbor’s novel precision editors Arbor’s portfolio of novel gene editors has significant therapeutic potential because of their unique protospacerRead More
Nov 7, 2023
Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of R. Nolan Townsend to the Company’s Board of Directors. Mr. Townsend is the Chief Executive Officer of LEXEO Therapeutics, a clinicalRead More
Aug 29, 2023
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer. Mr. Tamboli brings over 24 years of health care experience to the role,Read More
Aug 7, 2023
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Deanna M. Petersen, MBA, as its Chief Business Officer. Ms. Petersen joins Arbor from AVROBIO, Inc., where she served as ChiefRead More
May 23, 2023
May 2, 2023
Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that three abstracts were selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being heldRead More
Apr 12, 2023
Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer. Dr. Ory joins Arbor from Casma Therapeutics, a Third Rock Ventures start up,Read More
Apr 6, 2023
Arbor Biotechnologies to Present at 2023 Cell & Gene Meeting on the Med
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor’s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at theRead More
Jan 11, 2023
Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase
Arbor Biotechnologies® (Arbor) today announced the expansion of an existing strategic collaboration covering in vivo genetic medicines by which Vertex Pharmaceuticals Incorporated (Vertex) will receive rights to Arbor’s novel precision editing technology for up to three diseases. Under the termsRead More
Jan 4, 2023
Arbor Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT.
Oct 20, 2022
Arbor Biotechnologies’ CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., has been elected as the Chairman of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.
Oct 4, 2022
Arbor Biotechnologies to Participate in the 2022 Cell & Gene Meeting on the Mesa
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that senior management will participate in a panel discussion and present a corporate overview at the 2022 Cell & Gene Meeting on the Mesa.
Sep 22, 2022
Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.
Sep 12, 2022
Arbor Biotechnologies Named One of Fierce Biotech’s “Fierce 15” Companies of 2022
Arbor Biotechnologies® today announced that Fierce Biotech has named it as one of 2022’s “Fierce 15” biotechnology companies, designating it as one of the most promising early stage biotechnology companies in the industry.
Sep 1, 2022
Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September.
Aug 25, 2022
Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).
Aug 2, 2022
Arbor Biotechnologies Appoints Lee Ann Marchionna as Chief People Officer
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Lee Ann Marchionna, MBA, to the newly created role of Chief People Officer. Ms. Marchionna joins Arbor® with more than 25 years of experience in Human Resources, having led organizational effectiveness initiatives as well as establishing talent, culture, and engagement practices for both public and private life sciences companies.
May 3, 2022
Arbor Biotechnologies to Present at the Bank of America Global Healthcare Conference
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in the upcoming Bank of America Global Healthcare Conference in Las Vegas, NV.
May 2, 2022
Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene & Cell Therapy
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced upcoming preclinical data presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-19, 2022, in Washington, D.C.
Feb 22, 2022
Arbor Biotechnologies Appoints Steven J. Favaloro as Chief Financial Officer
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Steven J. Favaloro as Chief Financial Officer.
Feb 8, 2022
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs
EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor®’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.
Jan 10, 2022
Arbor Biotechnologies to Present at the 40th Annual J.P. Morgan Healthcare Conference
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Jan 4, 2022
TCR2 Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, and Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies.
Nov 9, 2021
Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing.
Aug 24, 2021
Vertex and Arbor Establish New Partnership
The new agreement will enhance efforts in developing ex vivo engineered cell therapies using Arbor®‘s proprietary CRISPR gene editing technology for select diseases.
Jun 23, 2021
Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team
Pam Stetkiewicz, Ph.D., named Chief Operating Officer, and Kathryn McCabe, Ph.D., joins as SVP, Head of Business Development
Jun 21, 2021
Arbor Biotechnologies to Present at the Raymond James Human Health Innovation Conference
Devyn Smith, CEO, and other members of Arbor®’s management team will participate in one-on-one meetings with life science investors at the event.
Jun 1, 2021
Arbor Biotechnologies to Present at the Evercore ISI GenomeRx Emerging Therapeutics Conference and the Jefferies Virtual Healthcare Conference
Devyn Smith, CEO, and other members of Arbor®’s management team will participate in one-on-one meetings with life science investors at both events.
May 27, 2021
Arbor Continues to Build Therapeutic Focus with Key Scientific Leaders
John Murphy, Ph.D., named Chief Scientific Officer and Greg Hoffman, Ph.D., joins as VP, Discovery & Platform
Apr 1, 2021
Arbor Announces Devyn Smith, Ph.D., to Join as CEO
Dr. Smith brings significant cell and gene therapy development and platform experience from his 20+ year career at Sigilon Therapeutics and Pfizer Inc.
Mar 3, 2021
Arbor Announces Addition of Mark Angelino to Board of Directors
Arbor Biotechnologies® announced today the appointment of Mark D. Angelino, co-founder and former Chief Operating Officer of Generation Bio, to its Board of Directors. Mark brings significant company building and product development experience to the Arbor Board, given his expertiseRead More
Dec 23, 2020
Arbor and Lonza Announce Licensing Deal
The new agreement will provide Lonza with access to Arbor®‘s gene editing technology
Sep 29, 2020
Vor Biopharma and Arbor Biotechnologies Announce Collaboration
Vor will use Arbor®‘s proprietary gene editing technologies to develop therapies for the treatment of blood cancers.
Sep 25, 2019
Arbor Biotechnologies Announces Issuance of U.S. Patent for CRISPR-Cas13d
Arbor Biotechnologies®, an early-stage life sciences company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,392,616 entitled, “CRISPR RNA Targeting Enzymes and Systems and Uses Thereof.” The patent is based on Arbor’sRead More
Jul 9, 2019
Arbor Biotechnologies Selected for MIT STEX25
Arbor Biotechnologies® (Arbor), an early-stage biodiscovery company, announced today that it has been selected for STEX25, an MIT Startup Exchange featuring 25 industry-ready startups that are poised for significant growth. Arbor joins eight other companies chosen for the current session.Read More
Jan 3, 2019
Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies
Multi-year research collaboration funded by Vertex using Arbor®’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases
Jan 3, 2019
Arbor Biotechnologies Announces New Type V CRISPR-Cas System Discoveries and Addition to its Board
Arbor Biotechnologies® (Arbor), an early-stage life sciences company, today announced significant milestones including the discovery of multiple new type V CRISPR-Cas systems, published in the journal Science, and the appointment of Paul Meister to the Arbor Board of Directors. EarlierRead More
Jul 23, 2018
Arbor Biotechnologies Strengthens Leadership Team Names Daniel Maarten Janse Chief Business Officer
Arbor Biotechnologies®, an early stage biodiscovery company, today announced it has strengthened its leadership team with the appointment of Daniel Maarten Janse as Chief Business Officer. “Daniel’s strategic focus on business development and his extensive experience in early stage biodiscoveryRead More
